Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed May 25, 2023
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2023-05-25$1.22/sh−95,478$116,760→ 574,037 total - Award
Common Stock
2023-05-24+200,000→ 669,515 total - Award
Employee Stock Option (Right to buy)
2023-05-24+200,000→ 200,000 totalExercise: $0.41Exp: 2032-05-12→ Common Stock (200,000 underlying)
Footnotes (3)
- [F1]As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
- [F3]As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.